Stereotactic Radiation Therapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC)

Official Title

Stereotactic Radiation Therapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC): A Randomized Phase II Trial

Summary:

A multicentre randomized phase II trial of stereotactic body radiation therapy for oligo-progressive non-small cell lung cancer. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiation therapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).

Trial Description

Primary Outcome:

  • Progression-Free Survival
Secondary Outcome:
  • Overall Survival
  • Quality of Life
  • Toxicity
  • Lesional Control Rate
  • Total Time on Chemotherapy
  • Duration of current systemic agent treatment after SABR
  • Location of sites of further progression after SABR

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society